News

The 2015 Controlling Cancer Summit : Not too late to submit a poster

Off

www.cancersummit2015.com

Abstracts for poster presentation only can be submitted up to
two weeks before the event

You can download the instructions for authors at
www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf

EVENT DETAILS
12 May 2015 – 14 May 2015
LONDON, UK
With plenty of opportunity  for networking and debate, this informal international  meeting will bring you up to date with current research and thinking regarding cancer screening, prevention and treatment.  Presenters will include Clinicians, Academics and members of the Pharmaceutical industry and we encourage presentations from  the wide spectrum of cancer research, development and healthcare professionals.
Talks include:

ErbB-targeted CAR T-cell immunotherapy of cancer: a strategy to maximize the window of therapeutic opportunity.
Dr John Maher, Senior Lecturer in Immunology, NIHR Biomedical Research Centre at Guy¹s and St Thomas¹ NHS Foundation, Trust and King¹s College London, Research Oncology, Division of Cancer Studies, Guy’s Hospital campus, St Thomas St, London, United Kingdom

Current status of minimally invasive diagnosis and staging of lung malignancies
Dr Jorge Pascual, MD, Assistant Professor, Mayo Clinic College of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Florida, USA

Overcoming Mechanisms of Therapeutic Resistance in Advanced Castration Resistant Prostate Cancer
Dr Natasha Kyprianou, James F. Hardymon Chair in Urology Research, Professor of Urology, Molecular Biochemistry, Pathology and Toxicology, Combs, Rm 306, University of Kentucky College of Medicine, Lexington, KY, US

Breast Cancer, Chemo-resistance and ErbB receptors
Professor Zhixiang Wang, PhD, Department of Medical Genetics, Signal Transduction Research Group, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada

The role of intraoperative radiation therapy for retroperitoneal sarcomas
Dr Richard J. Gray, MD, FACS, Consultant, Section of Surgical Oncology, Program Director, General Surgery Residency, Associate Professor of Surgery, Mayo Clinic College of Medicine, Phoenix, AZ, US

EWAS and GWAS go together in cancer control
Dr Mukesh Verma, Ph.D., Branch Chief, Methods and Technologies Branch, Program Director. Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences. National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA

Experience of the European Institute of Oncology in the use of intra-operative radiotherapy with electrons (ELIOT)
Dr Simonetta Monti, Senior Assistant, Medico Assistente, Senology Division, Reparto di Senologia, Milano, Italy

New Imaging Methods for Assessing Tumor Response to Therapy
Dr Richard M. Gore, MD, Professor of Radiology, University of Chicago, Evanston Hospital, Evanston, IL, USA

Measuring Quality of Survival and Impact of Adverse Events on Quality of Life in Metastatic Disease
Dr Stacie Hudgens, MA (AbD), Managing Partner, Strategic Lead, Clinical Outcomes Solutions, Adjunct Professor at Center for Outcomes Research (COR), University of Illinois College of Medicine at Peoria and the College of Pharmacy, University of Arizona, USA
Dr Anna Forsythe, PharmD, MSc, MBA, Sr. Director Eisai Value Maximization Systems, Global Head Value and Access, Woodcliff Lake, USA

Reproductive Health Issues and Fertility Preservation for Young Adult Cancer Patients and Survivors
Dr Gwendolyn P. Quinn, Ph.D., Senior Member, Director Survey Methods Core, Professor, University of South Florida, Morsani College of Medicine, Tampa, FL , USA

Targeted alpha therapy for cancer & the use of radioisotopes
Dr Graeme Melville, Macquarie University, Sydney, Australia

Second line therapy in advanced non-small cell lung cancer (NSCLC)
Dr Mircea DEDIU MDPhD, Medical Oncology senior consultant, Chief of Medical Oncology Department, Institute of Oncology Bucharest, Bucharest, Romania

Vitamin D binding protein-based immunotherapy leads to reversal of the neoplastic phenotype and suppression of oncogene expression.
Dr Marco Ruggiero, Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Firenze, Italy.

Latest developments in non-melanoma skin cancer
Professor Patricia Tak Hing Tai, University of Saskatchewan, Regina, Saskatchewan, Canada

Involvement of key components of wnt signalling in human astrocytic brain tumours
Professor. Dr. sc. Nives Pećina-Šlaus, Department of Biology, Laboratory for Neurooncology, Croatian Institute for Brain Research, Medical School University of Zagreb, Zagreb, Croatia

Novel methods to assess and support older people with cancer; Comprehensive Care for Older People with Cancer (COCOC)
Professor Margot Ann Gosney, University of Reading, Clinical Health Sciences, Reading, UK

Cancer Causation and Risk Communication: The gap between cancer knowledge and community perceptions
Dr Bernard W. Stewart PhD FRACI DipLaw, Professor, Faculty of Medicine, UNSW and Head, Cancer Control Program, South East Sydney Public Health Unit, Locked Bag 88, Randwick, Australia

Lung Cancer CT Screening : Time for implementation
Professor John K Field, Director of Research, Roy Castle Lung Cancer Research Programme The University of Liverpool, Cancer Research Centre Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine Roy castle Building, Liverpool, UK

1st line chemotherapy in treatment of mCRC: FOLFIRI vs FOLFIRI+bevacizumab – single institution experience.
Dr Zoran Rakusic, MD, PhD, Head of Clinical Ward, Department of Oncology, University of Zagreb, Croatia

Early detection of oral carcionogenesis: the biological fundaments of in vivo optical imaging
Professor Rui Amaral Mendes, The Catholic University of Portugal and Case Western Reserve University, Cleveland, OH, USA

Prognostic value of repeat testing in population screening for CRC – for optimizing efficacy
Dr Pavel Elsakov MD PhD, State Reserch Institute, Innovative Medicine Center, Vilnius, Lithuania

Low-dose aspirin in the prevention and the treatment of cancer: evidence from randomised and observational studies
Professor Peter Creighton Elwood, Cardiff University, Penylan, Cardiff, United Kingdom

Cell-mediated anti-cancer immunotherapy; targeting chemotherapy-resistant malignant cells with personalized immunotherapy mediated by autologous and allogeneic cells
Professor Shimon Slavin, The International Center for Cell Therapy & Cancer Immunotherapy (CTCI), Weizman Center, Tel Aviv, Israel

www.cancersummit2015.com

Latest Euroscicon Tweets

  • Conventional Medication: #Euroscicon welcomes every one of the members from everywhere throughout the world to go t… https://t.co/rRdLgLoVZt
    about 7 hours ago